Finance

Beta
Lists
ABCL:NASDAQ
AbCellera Biologics Inc
$6.00
-5.81%
(-0.37) 1D
Jun 5, 10:55:34 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABCL...
Open
$6.20
High
$6.33
Low
$5.83
Mkt. cap
1.83B
Avg. vol.
9.55M
Volume
3.30M
52-wk high
$6.79
52-wk low
$2.38
EPS
-$0.48
Beta
1.18
Shares outstanding
305.38M
No. of employees
562
Open
$6.20
High
$6.33
Low
$5.83
Mkt. cap
1.83B
Avg. vol.
9.55M
Volume
3.30M
52-wk high
$6.79
52-wk low
$2.38
EPS
-$0.48
Beta
1.18
Shares outstanding
305.38M
No. of employees
562
Analyst outlook
Analyst Ratings
Based on 6 analysts giving stock ratings to ABCL in the past 3 months
Strong Buy
Buy
6
Hold
0
Sell
0
12 month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ABCL in the last 3 months.
Highest
Current $6.00
$13.00 (+116.67%)
Average
$9.40 (+56.67%)
Lowest
$7.00 (+16.67%)
News stories
From sources across the web
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth care
Websiteabcellera.com
Last report
May 11, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.14 / -$0.20
+29.11%beat
Revenue / Est. (USD)
8.32M / 5.66M
+47.04%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
17.08M
8.96M
44.85M
8.32M
Cost of goods sold
39.21M
55.03M
50.09M
-
Cost of revenue
39.21M
55.03M
50.09M
-
Research and development expenses
-
-
-
46.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21.99M
24.96M
17.22M
12.33M
Operating expense
27.46M
30.20M
23.34M
65.83M
Total operating expenses
66.67M
85.23M
73.44M
65.83M
Operating income
-49.58M
-76.28M
-28.58M
-57.52M
Other non operating income
5.65M
745.00K
2.16M
4.34M
EBT including unusual items
-36.34M
-68.77M
-19.50M
-49.54M
EBT excluding unusual items
-36.34M
-68.77M
-20.50M
-49.54M
Income tax expense
-1.62M
-11.65M
-10.55M
-6.37M
Effective tax rate
4.45%
16.94%
54.13%
12.86%
Other operating expenses
-
-
-
-
Net income
-34.73M
-57.12M
-8.94M
-43.16M
Net profit margin
-203.27%
-637.84%
-19.94%
-519.12%
Earnings per share
-0.12
-0.19
-0.03
-0.14
Interest and investment income
7.59M
6.76M
5.92M
3.64M
Interest expense
-
-
-
-
Net interest expenses
7.59M
6.76M
5.92M
3.64M
Depreciation and amortization charges
5.47M
5.25M
6.12M
6.84M
EBITDA
-44.11M
-71.03M
-22.46M
-50.68M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer